LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike

Rhea-AI Filing Summary

LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.

These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Litton Mark James

Role PRESIDENT and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	750,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 750,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 750,000 options Exercise price: $9.54 per share Underlying shares: 750,000 shares +2 more

5 metrics

Options granted 750,000 options Stock Option (Right to Buy) award to CEO

Exercise price $9.54 per share Strike price for the granted options

Underlying shares 750,000 shares Common stock underlying the options

Vesting period 48 months Monthly vesting from grant date

Expiration date April 8, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, vesting, Service Provider, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2026 Equity Incentive Plan financial

"defined in the Issuer's 2026 Equity Incentive Plan"

vesting financial

"scheduled to vest monthly over a term of 48 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Litton Mark James

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		750,000		(1)	04/08/2036	Common Stock	750,000	$0	750,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney-in-Fact for Mark James Litton	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio CEO Mark James Litton receive in this Form 4 filing?

Mark James Litton received a grant of stock options for 750,000 shares of LeonaBio common stock. These options are part of his compensation and give him the right to buy shares at a fixed exercise price of $9.54 per share before expiration.

What is the exercise price and expiration date of the LeonaBio CEO’s new options?

The granted options have an exercise price of $9.54 per share and expire on April 8, 2036. This means he can choose to purchase up to 750,000 shares at $9.54 any time before that expiration date, subject to vesting.

How do the 750,000 LeonaBio stock options vest for the CEO?

The 750,000 stock options vest in monthly installments over 48 months from the grant date. Each month, a portion becomes exercisable as long as Mark James Litton continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.

Is the Form 4 transaction for LeonaBio’s CEO a purchase or a grant?

The Form 4 records a grant/award acquisition of stock options, not an open-market share purchase. The transaction uses code “A,” indicating a compensation-related grant of derivative securities rather than a buy or sell on the public market.

How many LeonaBio option shares does the CEO hold after this transaction?

After this grant, Mark James Litton holds options covering 750,000 shares of LeonaBio common stock directly. This figure represents his total stock option position reported in this Form 4, tied to the new award with a $9.54 exercise price.